Check Eligibility for Generic Drug Price Inflation Settlement Compensation

Consumers who purchased specific generic drugs between May 2009 and December 2019 may now be eligible for financial compensation following a preliminary court approval. The U.S. District Court for the District of Connecticut granted preliminary approval this month for a distribution plan filed by a multistate coalition of 48 states and territories. The plan aims to return millions of dollars from settlement funds paid by generic drug manufacturers accused of conspiring to inflate prices.

A 96.5 Million Dollar Settlement Fund Targets Price Fixing

The distribution plan draws from settlements totaling approximately $96.5 million. Those agreements were reached with drug manufacturers Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure. The coalition’s legal actions trace back to a series of antitrust cases launched in 2016. The initial complaint named Heritage, 17 other corporate defendants, two individuals, and 15 generic drugs. A second complaint followed in 2019 against Teva Pharmaceuticals alongside 21 other large generic manufacturers and 16 senior executives.

A third complaint focuses on 80 topical generic drugs accounting for billions of dollars in U.S. sales, naming 26 corporate defendants and 10 individuals. A fourth complaint filed earlier this year alleges Novartis AG, Sandoz Group AG, and Sandoz AG are liable for Sandoz’s conduct and fraudulent asset transfers. The state investigations relied on millions of documents, extensive phone record databases, and evidence from several cooperating witnesses, including seven cooperating pharmaceutical executives. State officials stated that defendants utilized terms like fair share, playing nice in the sandbox, and responsible competitor to enforce an ingrained culture of collusion that unlawfully discouraged market competition.

How Affected Consumers Can File Claims for Compensation

Individuals who purchased eligible generic medications during the decade-long window are encouraged to verify their status. Consumers can visit www.AGGenericDrugs.com to check drug lists and submit claims online. Alternatively, claimants can call the toll-free hotline at 1-866-290-0182 or send inquiries via email to info@AGGenericDrugs.com.

Attorney General Dana Nessel emphasized that the legal action holds companies accountable for prioritizing corporate profits over consumer fairness. Similarly, Attorney General Jennifer Davenport noted that the recovery funds provide crucial relief for residents facing out-of-control prescription drug costs. The multistate coalition spans nearly nationwide participation, including Alaska, California, New York, Wyoming, Michigan, New Jersey, and dozens of other jurisdictions working in coordination to distribute the recovered capital directly back to impacted buyers.